[1] Weeder PD, Van Rijn R , Porte RJ . Machine perfusion in liver transplantation as a tool to prevent non-anastomotic biliary strictures: rationale, current evidence and future directions. J Hepatol, 2015, 63(1):265-275.
[2] Charlton M,Gane E,Manns MP,et al.Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis c virus infection after liver transplantation. Gastroenterology, 2015, 148(1):108-117.
[3] Axelrod DA , Vagefi PA , Roberts JP . The evolution of organ allocation for liver transplantation: tackling geographic disparity through broader sharing. Ann Surg, 2015, 262(2):224-227.
[4] 叶啟发,胡前超,钟自彪,等.289例中国公民逝世后器官捐献肝移植的临床疗效. 中华消化外科杂志, 2016, 15(5):461-465.
[5] 中华医学会感染病学分会肝衰竭与人工肝学组;中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2019,22(2):164-171.
[6] 丁蕾, 张振, 刘福全. 实时超声弹性成像技术对原位肝移植患者术后缺血型胆道病变临床评估价值分析. 实用肝脏病杂志, 2018, 21(6):963-966.
[7] Simone PD , Fagiuoli S , Cescon M , et al. Use ofeverolimus in liver transplantation: recommendations from a working group. Transplantation,2017, 101(2):239-251.
[8] Terrault NA , Mccaughan GW , Curry MP , et al. Internationalliver transplantation society consensus statement on hepatitis C management in liver transplant candidates.Transplantation, 2017, 101(5):945-955.
[9] Harimoto N , Yoshizumi T , Shimagaki T , et al. Inflammation-basedprognostic score in patients with living donor liver transplantation for hepatocellular carcinoma. Anticancer Res, 2016, 36(10):5537-5542.
[10] Chen JB , Chen GY , Wei SD , et al. Inflammatory factor in donor liver and its effect on recipient myocardial injury after liver transplantation. Eur Rev Med Pharmacol Sci, 2017, 21(19):4362-4368.
[11] Mark H. Simultaneous liver-kidney transplantation: shifting renal allograft gene expression from inflammation toward preservation. Kidney Int, 2017, 91(5):1010-1013.
[12] You Y,Zhang J,Gong J,et al.Mesenchymal stromal cell-dependent reprogramming of Kupffer cells is mediated by TNF-α and PGE2 and is crucial for liver transplant tolerance.Immunol Res, 2015, 62(3):292-305.
[13] Garrouste C , Anglicheau D , Kamar N , et al. Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients. Medicine, 2016, 95(41):e5108-e5110.
[14] Olmedo-Martín RV, Amo-Trillo V , González-Grande R, et al. Efficacy andsafety of anti–TNF-α agents in inflammatory bowel disease after liver transplant: a case series. Transpl P, 2018, 50(2):619-622.
[15] Azarpira N , Nikeghbalian S , Kazemi K , et al. Association ofincreased plasma interleukin-6 and TNF-α levels in donors with the complication rates in liver transplant recipients. Int J Organ Transplant Med, 2013, 4(1):9-14.
[16] Wenum MV, Adam AAA, Mark VA VD, et al. Oxygen drives hepatocyte differentiation and phenotype stability in liver cell lines. J Cell Commun Sign, 2018, 12(3):575-588.
[17] 陈璐,陆峰彬,叶韦玮,等.高脂饮食对自身免疫性肝炎肝损伤与焦亡的研究.中华传染病杂志,2018,36(1):18-24.
[18] Crins ND, Rver C, Goralczyk AD, et al.Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies.Pediatr transplant,2014,18(8):839-50.
[19] Millán O, Rafael-Valdivia L , San Segundo D , et al. Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplantresults of a multicentric study. Clin Immun, 2014, 154(2):141-154.
[20] Qiu M , Chen Y , Chen L , et al. Transforming growth factor β1 andFas ligand synergistically enhance immune tolerance in dendritic cells in livertransplantation. J Surg Res, 2017, 218:180-193. |